What is BCR-ABL and the Philadelphia Chromosome?
BCR-ABL is a fusion gene created by the Philadelphia chromosome—a t(9;22) translocation where part of chromosome 9 (containing the ABL gene) fuses with chromosome 22 (containing the BCR gene). This fusion protein constantly activates itself, driving uncontrolled growth of myeloid cells.
BCR-ABL is present in 100% of chronic myeloid leukemia (CML) cases and defines the disease. The discovery of tyrosine kinase inhibitors (TKIs) that target BCR-ABL revolutionized CML treatment from a fatal disease to one with near-normal life expectancy with appropriate therapy.
BCR-ABL Status in CML
Chronic Phase (CP)
Frequency: ~90% at diagnosis
Early phase with manageable disease. White blood cells slightly elevated, few blast cells. Responds well to tyrosine kinase inhibitors. 10-year survival >90% with appropriate TKI therapy.
Accelerated Phase (AP)
Frequency: ~5-10% at diagnosis
Intermediate phase with partial response to TKI. More blast cells and higher white count than chronic phase. Requires more intensive therapy, T315I testing, and possible stem cell transplant consideration.
Blast Crisis (BC)
Frequency: <5% at diagnosis
Advanced phase with many blast cells (20-30%). Behaves like acute leukemia. Survival is poor. Requires intensive therapy, stem cell transplant, and novel approaches including ponatinib for T315I-mutant disease.
Tyrosine Kinase Inhibitors (TKIs)
TKIs are the standard treatment for BCR-ABL+ CML, targeting the activated ABL kinase:
First-Generation TKI:
- Imatinib (Gleevec): First TKI, standard first-line therapy for most patients
Second-Generation TKIs:
- Dasatinib (Sprycel): More potent, faster molecular response than imatinib
- Nilotinib (Tasigna): Less myelosuppression, fewer side effects
- Bosutinib (Bosulif): Alternative second-generation option
Third-Generation TKI:
- Ponatinib (Iclusig): Only TKI that inhibits T315I-mutant BCR-ABL (resistance mutation)
Resistance Mutations
With long-term TKI use, CML cells can develop mutations that confer resistance:
- T315I (Gate-Keeper Mutation): Most common resistance mutation. Requires ponatinib
- Other mutations: E255K, Y253H, etc. May respond to alternative TKIs
- BCR-ABL amplification: Increased TKI dose or higher potency TKI needed
- Monitoring: Regular BCR-ABL mutation testing if TKI response inadequate
Treatment Goals and Monitoring
CML treatment aims for complete cytogenetic response and molecular remission:
- Complete cytogenetic response: No Philadelphia chromosome detected
- Major molecular response: BCR-ABL transcript reduced >3 logs
- Deep molecular response: BCR-ABL MR4/MR4.5 (very low/undetectable)
- Monitoring: Regular BCR-ABL PCR tests track response
Find Matching Trials →
Frequently Asked Questions
What is the Philadelphia chromosome?
▼
The Philadelphia chromosome is a t(9;22) translocation where parts of chromosomes 9 and 22 swap places:
- Creates the BCR-ABL fusion gene
- This gene produces a protein that constantly activates itself
- The overactive protein drives leukemia cell growth
- Found in 100% of CML cases and some acute leukemias
This was the first chromosomal abnormality linked to cancer (discovered in 1960) and led to the first targeted cancer therapy (imatinib/Gleevec).
What are tyrosine kinase inhibitors?
▼
TKIs are drugs that block the BCR-ABL protein:
- BCR-ABL is a tyrosine kinase—an enzyme that activates itself
- TKIs block this activation, stopping leukemia cell growth
- Cells then undergo programmed death (apoptosis)
- This targets the specific molecular abnormality driving CML
TKIs revolutionized CML treatment, transforming it from a fatal disease to a manageable chronic condition.
What is my expected survival with CML?
▼
With modern tyrosine kinase inhibitor therapy, CML survival has improved dramatically:
- Chronic phase at diagnosis: >90% 10-year survival with appropriate TKI
- Accelerated phase: 50-70% 5-year survival
- Blast crisis: <30% 5-year survival
Most CML patients on TKI therapy have life expectancy similar to the general population if achieving complete response.
What does T315I mutation mean?
▼
T315I is a resistance mutation that develops in some CML cells:
- What it is: A point mutation in the BCR-ABL gene
- Effect: Changes the shape of BCR-ABL, preventing most TKIs from binding
- Resistance: Makes first and second-generation TKIs ineffective
- Treatment: Requires ponatinib, the only TKI that inhibits T315I
Regular BCR-ABL mutation testing helps detect T315I early and guide therapy.
Can I stop taking TKI if I achieve remission?
▼
For most CML patients, lifelong TKI therapy is standard:
- Some patients in deep molecular response may attempt TKI discontinuation in clinical trials
- Stopping requires close monitoring (molecular response assessed frequently)
- Approximately 40% can successfully discontinue; others restart TKI if response is lost
- Discontinuation should only be attempted under close medical supervision
Ask your oncologist if you're a candidate for trial discontinuation.
What clinical trials are available for CML?
▼
CML clinical trials explore:
- New TKI combinations and strategies
- Optimal treatment duration and intensity
- TKI discontinuation in deep remission
- Novel agents for TKI-resistant disease
- Allogeneic stem cell transplant optimization
BCR-ABL+ status makes you eligible for many CML-specific clinical trials.